During the corresponding time, Puretech Health Plc saw a revenue deteriorated by -3.5 % year on year, While revenue at the Puretech Health Plc's corporate clients
Puretech Health Plc's Comment on Sales, Marketing and Customers
In the European Union (EU), only medical devices and in vitro diagnostic medical devices (IVD MDs) bearing the CE mark may be marketed and advertised according to their intended purpose. Advertising and promotion activities are governed by EU legislation and national laws, which may restrict promotional efforts directed at the general public and healthcare professionals. Regulatory authorities within the EU and European Economic Area (EEA) possess broad powers to inspect companies, suppliers, and professional users, and to enforce compliance through various measures. The EU In Vitro Diagnostic Regulation (IVDR), effective since May 26, 2022, establishes an updated regulatory framework for IVD MDs aimed at enhancing public health and patient safety. The IVDR introduces a tiered implementation system to minimize supply disruptions and imposes new or strengthened requirements on manufacturers, including more rigorous rules for market placement and device surveillance.
Puretech Health Plc’s Comment on Sales, Marketing and Customers
In the European Union (EU), only medical devices and in vitro diagnostic medical devices (IVD MDs) bearing the CE mark may be marketed and advertised according to their intended purpose. Advertising and promotion activities are governed by EU legislation and national laws, which may restrict promotional efforts directed at the general public and healthcare professionals. Regulatory authorities within the EU and European Economic Area (EEA) possess broad powers to inspect companies, suppliers, and professional users, and to enforce compliance through various measures. The EU In Vitro Diagnostic Regulation (IVDR), effective since May 26, 2022, establishes an updated regulatory framework for IVD MDs aimed at enhancing public health and patient safety. The IVDR introduces a tiered implementation system to minimize supply disruptions and imposes new or strengthened requirements on manufacturers, including more rigorous rules for market placement and device surveillance.
Sources:
Puretech Health Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Puretech Health Plc’s corporate clients.
For your research, we’ve provided 9 tables on Puretech Health Plc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
100 %